Galectin Therapeutics Inc. (GALT) Drops 7.04% on January 12

Equities Staff |

Galectin Therapeutics Inc. (GALT) was one of the Russell 2000's biggest losers for Tuesday January 12 as the stock slid 7.04% to $1.32, a loss of $-0.0999 per share. Starting at an opening price of $1.43 a share, the stock traded between $1.24 and $1.43 over the course of the trading day. Volume was 77,632 shares over 180 trades, against an average daily volume of 130,478 shares and a total float of 23.93 million.

The losses send Galectin Therapeutics Inc. down to a market cap of $31.59 million. In the last year, Galectin Therapeutics Inc. has traded between $4.40 and $1.40, and its 50-day SMA is currently $2.06 and 200-day SMA is $2.54.

Galectin Therapeutics Inc is a clinical stage biopharmaceutical company. The Company is engaged in drug research and development to create new therapies for fibrotic disease and cancer.

Galectin Therapeutics Inc. is based out of Norcross, GA and has some 7 employees. Its CEO is Peter G. Traber.

For a complete fundamental analysis analysis of Galectin Therapeutics Inc., check out’s Stock Valuation Analysis report for GALT. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

IGEN Networks Corp.

iGen Networks Corp is engaged in investing in and managing for growth private high-tech companies that offer products and services in the domains of wireless broadband, software as a service,…

Private Markets

MyForce, Inc.

As parents, we constantly worry about the safety of our loved ones. The media bombards us with incidents from across the nation school shootings, frequent assaults on campuses, and crimes…


Uber connects riders with safe, reliable, convenient transportation providers at a variety of price-points in cities around the world. Uber makes money from charging their drivers 20% of the fare…